Humanin vs SS-31
Updated 13 sources
Key differences
- 1Humanin is a signalling peptide that acts on cell receptors; SS-31 sits on the inner mitochondrial membrane and stabilises cardiolipin.
- 2Humanin has never been given to people in a trial.
Side by side
Facts from each record, in the same words as their own pages.
| Humanin | SS-31 | |
|---|---|---|
| Category |
|
|
| Evidence |
|
|
| FDA status |
|
|
| WADA |
|
|
| Half-life |
|
|
| Routes |
|
|
| Forms |
|
|
| Reported doses |
|
|
| Most cited frequency |
|
|
| Vial sizes |
|
|
| Mixed vial keeps |
|
|
| Protocols on file |
|
|
Doses shown are what sources report, labelled by origin. Not medical advice.
Read each in full
Sources
13 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.
Clinical study5
- ClinicalTrials.gov search: humaninClinicalTrials.gov · checked Oct 24, 2026
- Yen K et al. 2020, full textPubMed Central · checked Oct 24, 2026
- Chin YP et al. 2013, Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents, EndocrinologyPubMed · checked Oct 24, 2026
- Roshanravan B et al. 2021, in vivo mitochondrial ATP production improved after a single dose of elamipretidePubMed Central · checked Oct 23, 2026
Regulatory6
- FDA briefing document, Cardiovascular and Renal Drugs Advisory Committee, October 10, 2024FDA · checked Oct 23, 2026
- Forzinity (elamipretide) prescribing information, NDA 215244FDA · checked Oct 23, 2026
- Bulk drug substances nominated for use in compounding under section 503A (interim categories 1 to 3)FDA · checked Oct 24, 2026
- Certain bulk drug substances for use in compounding that may present significant safety risksFDA · checked Oct 24, 2026
Competitor guide1
- Humaninpeptiq.io · checked Oct 24, 2026
Community-reported1
- Humanin: community protocols and reportspeptideprotocolwiki.com, via a competitor guide · checked Oct 24, 2026